Sign in

You're signed outSign in or to get full access.

Lynx1 Capital Management LP

CIK:0001910456
Hedge Fund
$310M AUM
15 holdings
Dorado, PR, USA
Founded:2022
5 employees
Latest filing:Jun 30, 2025

Lynx1 Capital Management LP is an investment advisory firm headquartered in Dorado, Puerto Rico. The firm is SEC-registered and operates as a hedge fund specializing in public equity investments, primarily focusing on biotechnology and healthcare sectors. It was founded in the early 2020s and manages portfolios on behalf of institutional and high-net-worth individuals. The firm maintains a small, specialized team with an emphasis on scientific, data-driven approaches to investment decisions.

Investment Strategy

Lynx1 Capital Management LP primarily invests in publicly-listed biotechnology and life sciences companies. Their strategy involves concentrated positions in a select number of companies with significant growth potential, utilizing in-depth fundamental analysis and sector expertise to identify opportunities. They focus on early-stage and innovative healthcare businesses, rebalancing holdings dynamically to capitalize on sector developments.

Latest 13F Filing Activity

Lynx1 Capital Management LP filed their most recent 13F report on Jun 30, 2025 disclosing 14 equity positions with a total 13F market value of $346M. The fund increased holdings in Stoke Therapeutics Inc., Merus N V, GH Research PLC among other positions. Lynx1 Capital Management LP reduced exposure to Allogene Therapeutics Inc., Ibio Inc., C4 Therapeutics Inc. among others.

Top Buys
S
STOKSTOKE THERAPEUTICS INC
+$26.2M
M
MRUSMERUS N V
+$16.5M
G
GHRSGH RESEARCH PLC
+$11.2M
C
CGEMCULLINAN THERAPEUTICS INC
+$8.8M
P
PTGXPROTAGONIST THERAPEUTICS INC
+$5.1M
Top Sells
P
PTGXPROTAGONIST THERAPEUTICS INC
+$5.1M
T
TCRXTSCAN THERAPEUTICS INC
+$4.0M
A
ALLOALLOGENE THERAPEUTICS INC
-$3.6M
I
IBIOIBIO INC
-$2.3M
C
CCCCC4 THERAPEUTICS INC
-$1.2M

Top Holdings

M
MRUSMERUS N V
+23.8%$82.5M
G
GHRSGH RESEARCH PLC
+23.8%$82.2M
S
STOKSTOKE THERAPEUTICS INC
+17.7%$61.3M
P
PTGXPROTAGONIST THERAPEUTICS INC
+11.7%$40.5M
C
CGEMCULLINAN THERAPEUTICS INC
+9.6%$33.1M

Equity Positions (14)

TickerSecurityWeightMarket ValueSharesAvg CostPriceChange (QoQ)
MERUS N V23.84%$82.5M1,568,841$36.34$52.60+$16.5M
GH RESEARCH PLC23.76%$82.2M6,746,951$10.15$12.19+$11.2M
STOKE THERAPEUTICS INC17.72%$61.3M5,404,674$8.50$11.35+$26.2M
PROTAGONIST THERAPEUTICS INC11.70%$40.5M733,014$48.36$55.27+$5.1M
CULLINAN THERAPEUTICS INC9.57%$33.1M4,400,842$9.30$7.53+$8.8M

Industry Allocation

PHARMACEUTICAL PREPARATIONS
+83.8%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+16.2%

Investment Team (2)

NameRoleLocationLinkedIn
B
Brian Chait
PresidentDelray Beach, FL , United States
D
Deidre Holt
Associate PartnerSacramento, CA , United States